A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma

Leão, Ricardo; Nayan, Madhur; Punjani, Nahid; Jewett, Michael A.S.; Fadaak, Kamel; Garisto, Juan; Lewin, Jeremy; Atenafu, Eshetu G.; Sweet, Joan; Anson‐Cartwright, Lynn; Boström, Peter J.; Chung, Peter; Warde, Padraig; Bedard, Philippe L.; Bagrodia, Aditya; Freifeld, Yuval; Power, Nicholas; Winquist, Eric; Hamilton, Robert J.

doi:10.1016/j.euf.2018.01.015

Cited by 30 publications

(37 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analysis of GI revealed hypermethylation of HM13 in NSTs and subtype-specific hypermethylation of H19 in TEs, while SEs (like GCNIS) were globally GI-erased, implying that focal methylation observed in NST samples might occur de novo after erasure, as suggested in other studies [124]. This might be of interest in the prediction of development of residual mature TE in case of patients with NST treated with chemotherapy [125]. Additionally, the authors explored differentially methylated genes among the various pure tumor entities: SEs, ECs, YSTs, CHs, and TEs.…”

Section: Taking Advantage Of the Developmental Model: Biomarkers Fmentioning

confidence: 69%

Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic

Lobo

Gillis

Jerónimo

et al. 2019

IJMS

110

View full text Add to dashboard Cite

Current (high throughput omics-based) data support the model that human (malignant) germ cell tumors are not initiated by somatic mutations, but, instead through a defined locked epigenetic status, representative of their cell of origin. This elegantly explains the role of both genetic susceptibility as well as environmental factors in the pathogenesis, referred to as ‘genvironment’. Moreover, it could also explain various epidemiological findings, including the rising incidence of this type of cancer in Western societies. In addition, it allows for identification of clinically relevant and informative biomarkers both for diagnosis and follow-up of individual patients. The current status of these findings will be discussed, including the use of high throughput DNA methylation profiling for determination of differentially methylated regions (DMRs) as well as chromosomal copy number variation (CNV). Finally, the potential value of methylation-specific tumor DNA fragments (i.e., XIST promotor) as well as embryonic microRNAs as molecular biomarkers for cancer detection in liquid biopsies will be presented.

show abstract

Section: Taking Advantage Of the Developmental Model: Biomarkers Fmentioning

confidence: 69%

Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic

Lobo

Gillis

Jerónimo

et al. 2019

IJMS

110

View full text Add to dashboard Cite

show abstract

“…Vergouwe y colaboradores en 2001 describieron un nomograma en donde toman en cuenta 6 variables: presencia de teratoma en el tumor primario, clasificación del teratoma: diferenciado o indeterminado, niveles de marcadores tumorales prequimioterpia, adicionalmente el nomograma creado por Leao y colaboradores en 2018 incluye presencia de teratoma en la histología inicial, alfa feto proteína pre quimioterapia, tamaño de la masa pre quimioterapia y cambio del tamaño de la masa residual. 18,19 Dentro de nuestros resultados el componente de teratoma en la histología testicular estuvo relacionado con aumento de tamaño de la masa residual, y este a su vez se relacionó con teratoma en la histología final.…”

Section: Discussionunclassified

Factores asociados a la histología de masa residual retroperitoneal post quimioterapia en tumor testicular de células germinales

Torres

Ramos

Varela

et al. 2020

Revista Urología Colombiana / Colombian Urology Journal

View full text Add to dashboard Cite

Resumen Objetivo El objetivo de este estudio es describir las características y factores relacionados con la histología de la masa residual postquimioterapia en pacientes con tumor de células germinales de origen testicular sometidos a linfadenectomía retroperitoneal durante 12 años de seguimiento. Métodos Retrospectivamente se recolectaron datos clínicos, quirúrgicos y patológicos de la historia clínica de los pacientes en un centro de referencia de manejo de cáncer durante un periodo de 12 años. Se estimó la asociación entre los datos recolectados con la histología del tumor residual post quimioterapia. Resultados Se incluyeron 64 pacientes, la edad promedio fue 28.1 años, el tamaño promedio de masa residual fue de 6.7 cm. La histología de la masa residual fue teratoma en 60.9%, necrosis 26.5% y tumor viable 12.5%. El grupo pronóstico tiene asociación con la histología de la masa retroperitoneal. Las masas con histología de necrosis tuvieron menor tamaño con media 6.5 cm mientras que otras histologías tuvieron tamaño promedio de la masa residual de 10.4 cm. Conclusiones La LNDRP-PC es el estándar de tratamiento en masas residuales retroperitoneales después de quimioterapia y puede generar sobre-tratamiento hasta en 50% de los casos. El teratoma en la histología testicular está relacionado mayor tamaño de la masa residual retroperitoneal. Las características histológicas de la masa residual son comparables con otras series.

show abstract

“…Several clinical nomograms have been proposed to identify the patients with necrosis/scar tissue only residual disease post-chemotherapy (57)(58)(59). However, the accuracy of those strategies is highly suboptimal and cannot and should not be routinely used for management decisions.…”

Section: Post-chemotherapy Residual Diseasementioning

confidence: 99%

Narrative review of developing new biomarkers for decision making in advanced testis cancer

Nappi

Nichols²,

Kollmannsberger

2021

Transl Androl Urol

View full text Add to dashboard Cite

Management of testicular germ cell tumor (GCT) patients is based on clinical determinants, mainly CT scan and serum tumor markers (alpha-fetoprotein, beta subunit of HCG and LDH). Treatment decisions are usually straightforward for patients with clear evidence of metastatic disease, confirmed either by imaging tests or by unequivocal elevated tumor markers. However, there are several clinical scenarios where the assessment of metastatic disease is complicated by the limited specificity of the current imaging tests and serum tumor markers. These include patients with clinical stage IIA GCT with negative tumor markers and patients with post-chemotherapy residual disease where, in absence of clear indicators of GCT,decision making and patient treatment allocation become challenging. Therefore, more accurate biomarkers are critical to reduce the risk of under-or over-treatment and to always deliver the most optimal therapy. The objectives of this narrative review are to review the available publications about micro-RNAs in GCT s and their potential clinical applications. Two clusters of micro-RNAs, miR-371a-3p and miR-302/367, specifically expressed by both seminoma and non-seminoma GCT and easily detectable in the peripheral blood, have demonstrated to be promising in this endeavor. Large prospective trials are ongoing to define the operating characteristics of these biomarkers and their clinical utility to improve GCT patient management and reduce the error rate deriving from clinical uncertainty, therefore reducing the risk of sub-optimal treatments.

show abstract

A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma

Cited by 30 publications

References 28 publications

Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic

Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic

Factores asociados a la histología de masa residual retroperitoneal post quimioterapia en tumor testicular de células germinales

Narrative review of developing new biomarkers for decision making in advanced testis cancer

Contact Info

Product

Resources

About